Success Metrics

Clinical Success Rate
86.0%

Based on 196 completed trials

Completion Rate
86%(196/228)
Active Trials
18(6%)
Results Posted
46%(91 trials)
Terminated
32(11%)

Phase Distribution

Ph phase_1
14
5%
Ph phase_2
34
12%
Ph early_phase_1
3
1%
Ph not_applicable
54
18%
Ph phase_3
52
18%
Ph phase_4
123
42%

Phase Distribution

17

Early Stage

34

Mid Stage

175

Late Stage

Phase Distribution280 total trials
Early Phase 1First-in-human
3(1.1%)
Phase 1Safety & dosage
14(5.0%)
Phase 2Efficacy & side effects
34(12.1%)
Phase 3Large-scale testing
52(18.6%)
Phase 4Post-market surveillance
123(43.9%)
N/ANon-phased studies
54(19.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.1%

196 of 233 finished

Non-Completion Rate

15.9%

37 ended early

Currently Active

18

trials recruiting

Total Trials

293

all time

Status Distribution
Active(20)
Completed(196)
Terminated(37)
Other(40)

Detailed Status

Completed196
unknown40
Terminated32
Recruiting14
Withdrawn5
Active, not recruiting4

Development Timeline

Analytics

Development Status

Total Trials
293
Active
18
Success Rate
86.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (1.1%)
Phase 114 (5.0%)
Phase 234 (12.1%)
Phase 352 (18.6%)
Phase 4123 (43.9%)
N/A54 (19.3%)

Trials by Status

completed19667%
terminated3211%
withdrawn52%
not_yet_recruiting21%
unknown4014%
recruiting145%
active_not_recruiting41%

Recent Activity

Clinical Trials (293)

Showing 20 of 293 trialsScroll for more
NCT06049797

A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

Active Not Recruiting
NCT03511118

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Recruiting
NCT06937476Not Applicable

Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole

Active Not Recruiting
NCT06705478Phase 2

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Recruiting
NCT07478796Phase 4

TDM-Guided Treatment With SSRIs in Hospitalized Adults and Children

Recruiting
NCT05901571Not Applicable

Acupuncture and Escitalopram for Treating Major Depression Clinical Study

Not Yet Recruiting
NCT05017311Phase 4

Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)

Recruiting
NCT07274241

Escitalopram and the Risk of Serious Adverse Events

Completed
NCT06216535Phase 2

Escitalopram in Asthma Patients With Frequent Exacerbation

Recruiting
NCT05603104Phase 3

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

Recruiting
NCT07331987Not Applicable

Efficacy and Safety of Probiotics for Anxiety Depression

Not Yet Recruiting
NCT05289830Phase 2

Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

Terminated
NCT05973786Phase 3

The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruiting
NCT03527043Phase 2

Impact of Escitalopram on Sperm DNA Fragmentation

Terminated
NCT07074652Not Applicable

The Effect of SSRIs on Threat of Shock Potentiated Neural Circuitry

Completed
NCT03887624Early Phase 1

Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.

Completed
NCT05536414Phase 2

Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder

Completed
NCT00958633Phase 3

Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.

Terminated
NCT03852160Phase 3

A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

Withdrawn
NCT06828887Phase 2

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
293